Article Text

Download PDFPDF
Humoral response to conjugate pneumococcal vaccine in paediatric oncology patients
  1. Frankie Wai Tsoi Cheng1,
  2. Margaret Ip2,
  3. Yvonne Yuen Ling Chu1,
  4. Zheng Lin2,
  5. Vincent Lee1,
  6. Ming Kong Shing1,
  7. Wing Kwan Leung1,
  8. Patrick Man Pan Yuen1,
  9. Chi Kong Li1
  1. 1Department of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
  2. 2Department of Microbiology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
  1. Correspondence to Frankie Wai Tsoi Cheng, Department of Paediatrics, 6/F, Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong; frankiecheng{at}


Objective Pneumococcal conjugate vaccine (PCV) is an effective way to prevent invasive pneumococcal diseases in high risk populations. The efficacy of this vaccine in paediatric oncology patients remains unknown.

Design and setting The authors evaluated the antibody response to seven pneumococcal serotypes in paediatric oncology patients given two doses of heptavalent PCV (PCV-7).

Results Forty-four patients (20 males; 24 females) with median age 9.5 years were studied. After two doses of PCV-7, 86–100% of patients had protective antibody titres against the seven vaccine serotypes. Increases in geometric mean antibody concentrations ranged from 3.8-fold for serotype 19F to 85.8-fold for serotype 14. There was no documented invasive pneumococcal disease in our cohort during the study period.

Conclusion PCV can elicit protective antipneumococcal antibody responses in paediatric oncology patients.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding Hong Kong Paediatric Bone Marrow Transplant Fund Research Grant.

  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the Joint CUHK-NTEC Clinical Research Ethics Committee.

  • Provenance and peer review Not commissioned; externally peer reviewed.